Table 3.
Univariate and multivariate analysis of the association between clinical characteristics and progression-free survival of colorectal-cancer patients
| Characteristic | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex | <0.001 | 0.001 | ||
| Male | 1.00 | 1.00 | ||
| Female | 0.86 (0.81–0.92) | 0.91 (0.85–0.96) | ||
| Age | <0.001 | <0.001 | ||
| <60 years | 1.00 | 1.00 | ||
| ≥60 years | 1.23 (1.15–1.30) | 1.42 (1.33–1.51) | ||
| Family history | 0.008 | 0.015 | ||
| No | 1.00 | 1.00 | ||
| Yes | 0.84 (0.73–0.96) | 0.85 (0.74–0.97) | ||
| Location | 0.530 | |||
| Right-sided colon | 1.00 | |||
| Left-sided colon | 0.97 (0.89–1.05) | |||
| Rectum | 1.01 (0.93–1.08) | |||
| Differentiation status | <0.001 | <0.001 | ||
| High | 1.00 | 1.00 | ||
| Moderate | 1.53 (1.38–1.70) | 1.10 (0.98–1.22) | ||
| Poor/undifferentiated | 2.72 (2.41–3.07) | 1.37 (1.20–1.57) | ||
| pT category | <0.001 | <0.001 | ||
| T1 | 1.00 | 1.00 | ||
| T2 | 1.79 (1.48–2.17) | 1.56 (1.28–1.91) | ||
| T3 | 3.20 (2.71–3.78) | 2.10 (1.65–2.66) | ||
| T4 | 5.59 (4.72–6.61) | 2.78 (2.18–3.53) | ||
| pN category | <0.001 | <0.001 | ||
| N0 | 1.00 | 1.00 | ||
| N1 | 2.10 (1.96–2.25) | 1.24 (1.10–1.41) | ||
| N2 | 3.92 (3.64–4.22) | 1.87 (1.65–2.11) | ||
| pM category | <0.001 | <0.001 | ||
| M0 | 1.00 | 1.00 | ||
| M1 | 6.08 (5.70–6.48) | 4.81 (3.89–5.95) | ||
| Clinical stage | <0.001 | <0.001 | ||
| I | 1.00 | 1.00 | ||
| II | 1.74 (1.55–1.96) | 1.05 (0.86–1.29) | ||
| III | 3.35 (2.99–3.75) | 1.65 (1.33–2.05) | ||
| IV | 12.60 (11.22–14.15) | 4.81 (3.89–5.95) | ||
| Pathologic subtype | <0.001 | 0.676 | ||
| Adenocarcinoma | 1.00 | 1.00 | ||
| MA and SRCC | 1.49 (1.35–1.63) | 1.05 (0.95–1.16) | ||
| Othersa | 0.66 (0.55–0.79) | 1.01 (0.84–1.23) | ||
| Operation | <0.001 | <0.001 | ||
| Radical | 1.00 | 1.00 | ||
| Palliative | 5.51 (5.06–6.00) | 1.71 (1.52–1.91) | ||
| Surgical margin | <0.001 | 0.030 | ||
| Negative | 1.00 | 1.00 | ||
| Positive | 4.82 (4.34–5.34) | 1.15 (1.01–1.31) | ||
| Chemotherapy | <0.001 | <0.001 | ||
| No | 1.00 | 1.00 | ||
| Yes | 1.27 (1.20–1.35) | 0.74 (0.69–0.97) | ||
a
Other pathologic subtypes include gastrointestinal stromal tumors, adenosquamous carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, malignant melanoma, lymph hematopoietic neoplasms, and gastrointestinal mesenchymal tumors.
MA, mucinous adenocarcinoma; SRCC, signet-ring cell carcinoma.